ArticleNature communications2020
Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits.
Registry-linked trialOpen access · goldFull text read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07527247 (Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity), which is not on this map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
1.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity
Who cites it
49 citing papers in PubMed, 76 citations in OpenAlex.
- Gut microbiota and immunometabolism in obesity.Gut microbes · 2026Review
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- [Research progress on poor response, resistance mechanisms, and influencing factors of immunotherapy for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances.Infection and immunity · 2026Review
- The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.Nature reviews. Urology · 2026Review
- Essential role of MHC II in the antitubercular efficacy of pyrazinamide.Antimicrobial agents and chemotherapy · 2026Article
- Autophagy in tuberculosis: advances, translational gaps, and the promise of host-directed therapies.Frontiers in cellular and infection microbiology · 2026Review
- Metformin modulates the phenotypes of tumor-associated macrophages in glioblastoma in a context-dependent manner by promoting the homeostasis of macrophages.Frontiers in oncology · 2026Article
- MDM2-P53-V-ATPases axis driven by dehydroevodiamine to fight intracellular bacterial infection.Communications biology · 2025Article
- Metabolic reprogramming of immune cells in the battle against intracellular bacterial chronic infections: novel mechanisms and breakthroughs.Molecular biology reports · 2025Review
- Metformin improves CD8+ T cell responses and parasitemia control via macrophage modulation during Trypanosoma cruzi infection.Journal of leukocyte biology · 2025Article
- Understanding and improving vaccine efficacy in older adults.Nature aging · 2025Review
- Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma.International journal of biological sciences · 2025Article
- Metformin and bone metabolism: unraveling their direct and indirect effects.Therapeutic advances in endocrinology and metabolism · 2025Review
- Masterful macrophages: understanding and targeting activation dysfunction in diabetic wounds.Burns & trauma · 2025Review
- The role of metformin in tuberculosis control among TB and diabetes mellitus comorbid individuals.Frontiers in microbiology · 2025Review
- T Cell Aging: An Important Target for Perioperative Immunomodulation.Clinical interventions in aging · 2025Review
- Repurposed Drugs and Plant-Derived Natural Products as Potential Host-Directed Therapeutic Candidates for Tuberculosis.Biomolecules · 2024Review
- Metformin Alters Tumor Immune Microenvironment, Improving the Outcomes of Breast Cancer Patients With Type 2 Diabetes Mellitus.Journal of breast cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 5 countries.
Julia BöhmeSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Nuria MartinezDepartment of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.
Shamin LiSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Andrea LeeSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Mardiana MarzukiSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Anteneh Mehari TizazuSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
David AckartDepartment of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, 80525-1601, USA.
Jessica Haugen FrenkelDepartment of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, 80525-1601, USA.
Alexandra ToddDepartment of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, 80525-1601, USA.
Ekta LachmandasDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Josephine LumSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Foo ShihuiSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Tze Pin NgGerontology Research Programme, Yong Loo Lin School of Medicine, Department of Psychological Medicine, National University Health System, National University of Singapore, Singapore, Singapore.
Bernett LeeSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Anis LarbiSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0003-2421-6052
Randall BasarabaDepartment of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, 80525-1601, USA.
Reinout van CrevelDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Evan NewellSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.ORCID 0000-0002-2889-243X
Hardy KornfeldDepartment of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.ORCID 0000-0002-8970-7306
Amit SinghalSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore. Amit_Singhal@immunol.a-star.edu.sg.ORCID 0000-0003-3913-8798
Agency for Science, Technology and Research · SGColorado State University · USRadboud University Nijmegen · NLUniversity of Massachusetts Chan Medical School · USNational University of Singapore · SGUniversity of Bonn · DE
Funding
Metabolomics Core U19AI111224 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY, MEGAN, MURRAY, MEGAN B · 2015 to 2021
$20.4MImpact of Diabetes and Hyperlipidemia on Host DefenseR01HL081149 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KORNFELD, HARDY · 2006 to 2019
$5.3MLung-Protective Mechanisms of Metformin in TBR01HL152078 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KORNFELD, HARDY, SINGHAL, AMIT · 2021 to 2024
$2.5MNHLBI NIH HHS R01 HL081149NHLBI NIH HHS R01 HL152078NIAID NIH HHS U19 AI111224
Abstract
Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium tuberculosis infection, progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence, when being treated with metformin. However, a detailed mechanistic understanding of these protective effects is lacking. Here, we use mass cytometry to show that metformin treatment expands a population of memory-like antigen-inexperienced CD8
Indexed as
AnimalsBCG VaccineCD8-Positive T-LymphocytesDiabetes Mellitus, Type 2FemaleGuinea PigsHumansHypoglycemic AgentsMaleMetforminMiceMycobacterium tuberculosisTuberculosisBCG VaccineHypoglycemic AgentsMetformin
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
Read underepoch 390
Registered trials
NCT07527247ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.